This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The overall goal of this program is to develop a fully ambulatory monitoring system that improves the method in which hot flash symptoms are objectively assessed in order for researchers to better evaluate safety and efficacy of new treatments in clinical trials. Hot flash symptoms are uncomfortable episodes that affect the lives of menopausal women and cancer (breast, prostate and ovarian) patients. This rapidly growing population is increasingly seeking alternative therapies due to negative consequences of the estrogen-progestin therapy, however efficacies of these alternative therapies are not clearly understood. Current hot flash monitoring methods and technologies are limited by compliance related issues, technology limitations including comfort of monitoring system, monitoring period and cost. PhiloMetron proposes to develop a low cost, fully ambulatory hot flash monitoring system that will utilize regional bioelectric impedance spectroscopy (BIS) as its core measurement technology. In this proof of concept program PhiloMetron will utilize the following two step research plan to validate the proposed system has equivalent performance to current methods for the detection of hot flash events - self reporting and sternal skin conductance (SSC). Accordingly, the following research design tasks are proposed: Task 1 - Bench System Characterization Induced Hot Flashes - This task will determine which combination of BIS, skin temperature and dermal heat flux measurements provide the best correlation to self reported hot flashes and sternal skin conductance in a controlled laboratory setting evaluated at three body locations. Task 2 Ambulatory System Performance in Home Setting - This task will characterize the performance of the PhiloMetron ambulatory monitoring system using the measurement site and parameters selected from data obtained in Task 1 as compared to subject self report and sternal skin conductance. If this proof of concept program is successful, a new avenue for low cost, fully ambulatory hot flash monitoring system more suited for at-home studies than current methods will be established. Future phase II studies of this device will be conducted to demonstrate its utility for future clinical trials evaluating the effectiveness of alternative therapies for treating hot flashes. This new system will provide a more effective means to evaluate new compounds and alternative therapies in an effort to reduce the impact hot flash symptoms have on this rapidly growing patient population quality of life.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR000750-34
Application #
7379168
Study Section
Special Emphasis Panel (ZRR1-CR-8 (01))
Project Start
2005-12-01
Project End
2006-11-30
Budget Start
2005-12-01
Budget End
2006-11-30
Support Year
34
Fiscal Year
2006
Total Cost
$1,212
Indirect Cost
Name
Indiana University-Purdue University at Indianapolis
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
603007902
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Robinson-Cohen, Cassianne; Bartz, Traci M; Lai, Dongbing et al. (2018) Genetic Variants Associated with Circulating Fibroblast Growth Factor 23. J Am Soc Nephrol 29:2583-2592
Askie, Lisa M; Darlow, Brian A; Finer, Neil et al. (2018) Association Between Oxygen Saturation Targeting and Death or Disability in Extremely Preterm Infants in the Neonatal Oxygenation Prospective Meta-analysis Collaboration. JAMA 319:2190-2201
Srinivasan, Lakshmi; Page, Grier; Kirpalani, Haresh et al. (2017) Genome-wide association study of sepsis in extremely premature infants. Arch Dis Child Fetal Neonatal Ed 102:F439-F445
Gupta, Samir K; Yeh, Eunice; Kitch, Douglas W et al. (2017) Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s. J Antimicrob Chemother 72:2042-2048
Robarge, Jason D; Desta, Zereunesay; Nguyen, Anne T et al. (2017) Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer. Breast Cancer Res Treat 161:453-461
Hertz, Daniel L; Speth, Kelly A; Kidwell, Kelley M et al. (2017) Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients. Breast Cancer Res Treat 165:659-668
Patel, Yash R; Kirkman, M Sue; Considine, Robert V et al. (2017) Retinopathy predicts progression of fasting plasma glucose: An Early Diabetes Intervention Program (EDIP) analysis. J Diabetes Complications 31:605-610
Robarge, Jason D; Metzger, Ingrid F; Lu, Jessica et al. (2017) Population Pharmacokinetic Modeling To Estimate the Contributions of Genetic and Nongenetic Factors to Efavirenz Disposition. Antimicrob Agents Chemother 61:
Hertz, D L; Kidwell, K M; Seewald, N J et al. (2017) Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer. Pharmacogenomics J 17:521-527
Kadakia, Kunal C; Kidwell, Kelley M; Seewald, Nicholas J et al. (2017) Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors. Breast Cancer Res Treat 164:411-419

Showing the most recent 10 out of 767 publications